- Home
- ITCI
as 11-20-2024 4:00pm EST
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 8.0B | IPO Year: | N/A |
| Target Price: | $97.67 | AVG Volume (30 days): | 747.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $58.14 - $93.45 | Next Earning Date: | 10-30-2024 |
| Revenue: | $613,728,000 | Revenue Growth: | 46.08% |
| Revenue Growth (this year): | 48.25% | Revenue Growth (next year): | 38.47% |
Stock Insider Trading Activity of Intra-Cellular Therapies Inc. (ITCI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Halstead Michael | ITCI | President | Nov 12 '24 | Sell | $89.27 | 41,583 | $3,692,100.03 | 7,764 | |
| Mates Sharon | ITCI | Chairman and CEO | Aug 29 '24 | Sell | $72.94 | 70,000 | $5,089,235.50 | 1,076,101 | |
| Mates Sharon | ITCI | Chairman and CEO | Aug 26 '24 | Sell | $73.66 | 95,925 | $7,054,085.49 | 1,076,101 |
Latest Intra-Cellular Therapies Inc. News
ITCI Breaking Stock News: Dive into ITCI Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
UBS Raises Price Target on Intra-Cellular Therapies to $87 From $79, Maintains Neutral Rating
GlobeNewswire
2 days ago
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
MT Newswires
6 days ago
Intra-Cellular Therapies Insider Sold Shares Worth $3,692,100, According to a Recent SEC Filing
GlobeNewswire
14 days ago
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
Pharmaceutical Technology
15 days ago
Intra-Cellular bolsters Caplyta data with another Phase III win
Clinical Trials Arena
15 days ago
Intra-Cellular bolsters Caplyta data with another Phase III win
GlobeNewswire
16 days ago
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia
Simply Wall St.
19 days ago
Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results
Compare ITCI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ITCI Intra-Cellular Therapies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.